ATYR Price / FCF | aTYR PHARMA INC

aTYR PHARMA INC Price-FCF Ratio

The price-to-free-cash-flow (P/FCF) ratio tells you how many dollars investors pay for each dollar of cash a company generates after paying for its capital spending. It is market capitalization divided by free cash flow over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher ratio means investors are paying more for each dollar of free cash flow; a negative ratio means the company spent more cash than it generated over those quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

aTYR PHARMA INC price-fcf ratio for the quarter ending 2026-06-30 was -1.09, a change of 7.35 year-over-year.
aTYR PHARMA INC price-fcf ratio for the quarter ending 2026-03-31 was -1.28, a change of 3.04 year-over-year.
aTYR PHARMA INC price-fcf ratio for the quarter ending 2025-12-31 was -1.23, a change of 3.17 year-over-year.
aTYR PHARMA INC price-fcf ratio for the quarter ending 2025-09-30 was -1.12, a change of 0.87 year-over-year.
aTYR PHARMA INC price-fcf ratio for fiscal 2026 was -1.09.
aTYR PHARMA INC price-fcf ratio for fiscal 2025 was -1.23, a change of 3.17 from fiscal 2024.
aTYR PHARMA INC price-fcf ratio for fiscal 2024 was -4.4, a change of -2.01 from fiscal 2023.
aTYR PHARMA INC price-fcf ratio for fiscal 2023 was -2.38, a change of -0.9 from fiscal 2022.

Available history: 2015-06-30 to 2026-06-30
Data captured: 2026-06-30

Historical Price-FCF Ratio

Date	Price-FCF Ratio	Market capitalization	Free cash flow 12 month
2026-06-30	-1.09	$59.81M	-$54.82M
2026-03-31	-1.28	$76.11M	-$59.3M
2025-12-31	-1.23	$76.18M	-$62.06M
2025-09-30	-1.12	$70.68M	-$62.99M
2025-06-30	-8.44	$469.93M	-$55.65M
2025-03-31	-4.32	$268.79M	-$62.21M
2024-12-31	-4.4	$304.22M	-$69.18M
2024-09-30	-1.99	$133.43M	-$67.11M
2024-06-30	-1.85	$118.24M	-$64.05M
2024-03-31	-2.3	$133.29M	-$58M
2023-12-31	-2.38	$89.23M	-$37.44M
2023-09-30	-2.44	$92.52M	-$37.85M
2023-06-30	-3.05	$123.22M	-$40.44M
2023-03-31	-3.18	$112.01M	-$35.2M
2022-12-31	-1.48	$64.6M	-$43.53M
2022-09-30	-2.17	$87.03M	-$40.14M
2022-06-30	-2.04	$79.6M	-$38.97M
2022-03-31	-3.99	$150.1M	-$37.59M
2021-12-31	-6.24	$207.61M	-$33.27M
2021-09-30	-8.25	$252.34M	-$30.57M
2021-06-30	-3.23	$79.58M	-$24.61M
2021-03-31	-3.07	$71.25M	-$23.24M
2020-12-31	-2.76	$42.75M	-$15.5M
2020-09-30	-2.14	$32.27M	-$15.05M
2020-06-30	-3.03	$41.66M	-$13.77M
2020-03-31	-2.15	$26.19M	-$12.17M
2019-12-31	-0.81	$16.23M	-$20.09M
2019-09-30	-0.68	$13.62M	-$19.98M
2019-06-30	-0.82	$18.09M	-$22.2M
2019-03-31	-10.06	$267.71M	-$26.62M
2018-12-31	-0.48	$15.18M	-$31.66M
2018-09-30	-9.12	$339.93M	-$37.28M
2018-06-30	-9.48	$380.38M	-$40.11M
2018-03-31	-33.35	$1.35B	-$40.6M
2017-12-31	-33.42	$1.46B	-$43.68M
2017-09-30	-46.74	$2.1B	-$44.95M
2017-06-30	-22.53	$1.13B	-$50.37M
2017-03-31	-21.26	$1.17B	-$54.81M
2016-12-31	-13.37	$714.72M	-$53.46M
2016-09-30	-20.43	$1.06B	-$51.67M
2016-06-30	-19.74	$923.09M	-$46.77M
2016-03-31	-29.78	$1.31B	-$43.86M
2015-12-31	-86.96	$3.26B	-$37.46M
2015-09-30	-101.94	$3.4B	-$33.31M
2015-06-30	-209.64	$6.13B	-$29.24M

Annual Price-FCF Ratio

Date	Price-FCF Ratio	Market capitalization	Free cash flow 12 month
2026-06-30	-1.09	$59.81M	-$54.82M
2025-12-31	-1.23	$76.18M	-$62.06M
2024-12-31	-4.4	$304.22M	-$69.18M
2023-12-31	-2.38	$89.23M	-$37.44M
2022-12-31	-1.48	$64.6M	-$43.53M
2021-12-31	-6.24	$207.61M	-$33.27M
2020-12-31	-2.76	$42.75M	-$15.5M
2019-12-31	-0.81	$16.23M	-$20.09M
2018-12-31	-0.48	$15.18M	-$31.66M
2017-12-31	-33.42	$1.46B	-$43.68M
2016-12-31	-13.37	$714.72M	-$53.46M
2015-12-31	-86.96	$3.26B	-$37.46M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Quince Therapeutics, Inc. (QNCX)	United States	$0.031B
CEL SCI CORP (CVM)	United States	$0.030B	-0.81
Scilex Holding Co (SCLX)	United States	$0.042B	-0.14
Metagenomi Therapeutics, Inc. (MGX)	United States	$0.044B	-0.48
Estrella Immunopharma, Inc. (ESLA)	United States	$0.020B
LeonaBio, Inc. (LONA)	United States	$0.047B	-0.61
Jasper Therapeutics, Inc. (JSPR)	United States	$0.020B	-0.37
Instil Bio, Inc. (TIL)	United States	$0.048B	-1.73
Tevogen Inc. (TVGN)	United States	$0.049B
BioCardia, Inc. (BCDA)	United States	$0.016B